Getinge B, SE0000202624

Analysts lift fair value for Getinge stock to SEK 251.70

Published on 10/05/2026 at 16:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter net income reached SEK 841.0 million. Getinge stock costs EUR 22.20 on October 5, 2026 after EUR 21.89, plus 1.42 percent.

Bauhaus-Poster mit Formen, Herzschlaglinie und Schriftzug MEDTECH in Primärfarben — Getinge AB (ISIN SE0000202624) wird hier als geometrisches Bauhaus-Poster mit Sektor-Kürzel MEDTECH und Herzschlaglinie dargestellt, Illustration mit AI erstellt.

Getinge stock was trading at EUR 22.20 at Lang & Schwarz on October 5, 2026, up 1.42 percent versus the prior close of EUR 21.89. Analysts raised the company's fair value estimate to SEK 251.70 from SEK 241.60 on September 30, 2026, according to Simply Wall St.

Profitability changed the debate

Getinge's second-quarter 2026 revenue reached SEK 8.381 billion, compared with SEK 8.238 billion in the second quarter of 2025. Net income increased to SEK 841.0 million from SEK 524.0 million, while net margin rose to 10.00 percent from 6.40 percent, according to Simply Wall St.

The comparison matters because the higher profit came with only a modest revenue increase. For investors, the margin improvement is therefore the central test behind the higher valuation rather than sales growth alone.

Guidance still depends on execution

In its second-quarter 2026 earnings call, Getinge reported organic net sales growth of 4.60 percent, organic order-intake growth of 6.20 percent and adjusted EBITA of SEK 1.478 billion, equal to an adjusted EBITA margin of 17.60 percent. The figures were published in the transcript carried by Yahoo Finance.

Management reiterated 2026 organic net sales growth guidance of 3.00-5.00 percent, adjusted for the phaseout of Surgical Perfusion. The same call put second-quarter free cash flow at SEK 1.0 billion and net debt at SEK 11.5 billion, leaving tariff exposure and product execution as the main counterweights to the margin recovery.

Target move meets a higher price

ABG Sundal Collier upgraded Getinge to Buy from Hold and raised its price target to SEK 285 from SEK 225 on September 7, 2026, as reported by MarketScreener. The target change reinforces the market's focus on earnings quality, but the latest fair value update also shows that higher expectations leave less room for operational setbacks.

On the primary listing, Getinge B was quoted at SEK 249.60 on Nasdaq Stockholm on October 5, 2026 at 4:32 p.m. CEST, according to structured market data. Its 52-week range was SEK 175.90 to SEK 251.40, placing the share near the upper end of that range.

Stock holds near its yearly high

Getinge's Lang & Schwarz price was EUR 22.20 on October 5, 2026 at 4:30 p.m. CEST, plus 1.42 percent versus the Lang & Schwarz prior close of EUR 21.89 on October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Getinge stock.